Company Product Description Indication Status Date

Phase II

Remegen Ltd., of Yantai, China

RC-18 (telitacicept)

TACI-Fc fusion protein

Systemic lupus erythematosus

Phase IIb trial met primary endpoint of a greater than 4-point reduction in the SLE responder Index (SRI4); 75.8% of patients achieved clinically meaningful disease activity improvement (p<0.001), as compared to placebo (33.9%)

11/14/19

Phase III

Everest Medicine Inc., of New York

Etrasimod

Oral sphingosine 1-phosphate receptor modulator

Moderately to severely active ulcerative colitis

Dosed first patient in trial assessing etrasimod for induction and maintenance therapy; about 330 patients will be enrolled in mainland China, South Korea and Taiwan

11/15/19

Hua Medicine Ltd., of Shanghai

Dorzagliatin (HMS-5552)

Dual-acting glucokinase activator

Type 2 diabetes

In the HMM0301 study, dorzagliatin produced a 1.07% HbA1c reduction from a baseline of 8.35% at 24 weeks compared to a reduction of 0.50% from a baseline of 8.37% for placebo (p<0.0001); 45.4% of patients taking dorzagliatin had an HbA1c of less than 7% compared to 21.5% of patients taking placebo (p<0.0001)

11/13/19

Notes

The date indicated refers to the BioWorld Clinical data table in which the news item can be found.

For more information about individual companies and/or products, see Cortellis.

No Comments